Abstract：
OBJECTIVE: The HeRO graft is a technique for vascular access in patients with limited treatment options; however, the published results with the HeRO graft are diverging. We therefore conducted a single-center study.
METHODS: Patient records between July 2014 and February 2020 from Vascular Access Unit of the Department of Vascular and Endovascular Surgery of University Clinic of Cologne (Germany) were reviewed. Retrospective data was analysed from patients with a HeRo graft (n = 18).
RESULTS: Eighteen patients were enrolled in the study. The mean age of the patients was 62.8 ± 17.24 years. During the follow-up period, no patients died from complications related to the HeRO graft. Each patient had a mean of 1.94 concomitant diseases. The primary patency rates of the HeRO graft at 3, 6, 12, 18, and 24 months were 61.1%, 50%, 16.7%, 11.1%, and 5.6%, respectively. The secondary patency rates at the same time intervals were 77.8%, 72.8%, 55.6% 55.6%, and 55.6%, respectively. There were 44 re-operations per year, or 2.4 operations per patient. The main cause of acute complications was acute graft occlusions after HERO graft implantation. An infection after the graft implantation occurred in five (27.7%) patients, leading to graft explanation in 2 cases.
CONCLUSIONS: The use of the HERO graft is a valuable alternative method for providing a durable dialysis access in patients with limited access options. The secondary patency and survival are good with a low infection rate.
METHODS: Patient records between July 2014 and February 2020 from Vascular Access Unit of the Department of Vascular and Endovascular Surgery of University Clinic of Cologne (Germany) were reviewed. Retrospective data was analysed from patients with a HeRo graft (n = 18).
RESULTS: Eighteen patients were enrolled in the study. The mean age of the patients was 62.8 ± 17.24 years. During the follow-up period, no patients died from complications related to the HeRO graft. Each patient had a mean of 1.94 concomitant diseases. The primary patency rates of the HeRO graft at 3, 6, 12, 18, and 24 months were 61.1%, 50%, 16.7%, 11.1%, and 5.6%, respectively. The secondary patency rates at the same time intervals were 77.8%, 72.8%, 55.6% 55.6%, and 55.6%, respectively. There were 44 re-operations per year, or 2.4 operations per patient. The main cause of acute complications was acute graft occlusions after HERO graft implantation. An infection after the graft implantation occurred in five (27.7%) patients, leading to graft explanation in 2 cases.
CONCLUSIONS: The use of the HERO graft is a valuable alternative method for providing a durable dialysis access in patients with limited access options. The secondary patency and survival are good with a low infection rate.
摘要：
目的：HeRO移植物是治疗方案有限的患者的血管通路技术；然而，与HeRO移植物的公开结果是不同的。因此，我们进行了单中心研究。
方法：回顾了2014年7月至2020年2月来自科隆大学诊所（德国）血管和血管内外科部门血管通路室的患者记录。回顾性分析了接受HeRo移植的患者（n=18）的回顾性数据。
结果：18名患者纳入研究。患者的平均年龄为62.8±17.24岁。在后续期间,没有患者死于与HeRO移植物相关的并发症。每位患者平均有1.94种伴随疾病。HeRO移植物在3、6、12、18和24个月的主要通畅率为61.1％，50%,16.7%,11.1%,5.6%，分别。相同时间间隔的二次通畅率为77.8%,72.8%,55.6%55.6%，55.6%,分别。每年有44次重新手术，或每位患者2.4次手术。急性并发症的主要原因是HERO移植物植入后的急性移植物闭塞。5例（27.7％）患者植入移植物后发生感染，导致2例移植解释。
结论：使用HERO移植物是一种有价值的替代方法，可为通道选择有限的患者提供持久的透析通道。继发性通畅性和存活率良好，感染率低。
方法：回顾了2014年7月至2020年2月来自科隆大学诊所（德国）血管和血管内外科部门血管通路室的患者记录。回顾性分析了接受HeRo移植的患者（n=18）的回顾性数据。
结果：18名患者纳入研究。患者的平均年龄为62.8±17.24岁。在后续期间,没有患者死于与HeRO移植物相关的并发症。每位患者平均有1.94种伴随疾病。HeRO移植物在3、6、12、18和24个月的主要通畅率为61.1％，50%,16.7%,11.1%,5.6%，分别。相同时间间隔的二次通畅率为77.8%,72.8%,55.6%55.6%，55.6%,分别。每年有44次重新手术，或每位患者2.4次手术。急性并发症的主要原因是HERO移植物植入后的急性移植物闭塞。5例（27.7％）患者植入移植物后发生感染，导致2例移植解释。
结论：使用HERO移植物是一种有价值的替代方法，可为通道选择有限的患者提供持久的透析通道。继发性通畅性和存活率良好，感染率低。
